3681.HK

The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

Retrieved on: 
星期二, 六月 21, 2022 - 7:38am

It also publishes the latest research papers in the field of immunology, including cellular immunology, immunochemistry and molecular immunology, immunogenetics and immunomodulation, immunopathology and clinical immunology, immunopharmacology, microbial immunology, oncology and transplantation.

Key Points: 
  • It also publishes the latest research papers in the field of immunology, including cellular immunology, immunochemistry and molecular immunology, immunogenetics and immunomodulation, immunopathology and clinical immunology, immunopharmacology, microbial immunology, oncology and transplantation.
  • The Company's flagship product SM03 (Suciraslimab) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA).
  • The Company's flagship product Suciraslimab is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis.
  • In contrast, the mechanism of action of Suciraslimab is very different from that of existing therapies on the market.

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

Retrieved on: 
星期三, 六月 15, 2022 - 5:03am

SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).

Key Points: 
  • SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).
  • Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial.
  • After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients.
  • Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage.

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Retrieved on: 
星期四, 六月 9, 2022 - 4:48am

The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.

Key Points: 
  • The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.
  • The present IND submission, once granted, will enable the Company to conduct clinical program in China for treatment of NMOSD.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety.
  • An IND application for NMOSD for SN1011 of SinoMab has been accepted by the CDE of the NMPA, and once approved, will facilitate the clinical research and development of new drugs for NMOSD in China.